Category: Regulatory Updates

The Regulatory Updates category provides timely coverage of new guidelines, draft revisions, and official communications from authorities such as the EMA, FDA, ICH, USP, and Ph. Eur. It highlights regulatory changes that affect GMP operations, product development, and quality systems.

Each update is presented with context, showing what it means for manufacturers, QA/RA professionals, Qualified Persons, and supply chain leaders. Topics range from revisions to GMP chapters and data integrity expectations to draft guidance on testing and validation.

If you don’t find what you are looking for, try using a different term or contact us.

New Drafts release in Pharmeuropa 37.4. October 2025.

Pharmeuropa 37.4: New Drafts Released for Public Consultation

Pharmeuropa 37.4 introduces updates to residual solvents (2.4.24), cannabis flower (3028), and rubber closures (3.2.9) to improve analytical clarity....
FDA New Guidance on CSA in 2025 - Featured Image

FDA’s 2025 Guidance on CSA: What Manufacturers Need to Know

FDA’s 2025 CSA guidance introduces a risk-based approach to software assurance, reducing burden and aligning with ISO 13485:2016 compliance....
Draft Revisions to EudraLex GMP Guide Chapter 1 – Pharmaceutical Quality System

Draft Revisions to EudraLex GMP Guide Chapter 1 – Pharmaceutical Quality System

Draft revisions to GMP Chapter 1 focus on risk-based oversight, early warning systems, supply chain risks, and improved Product Quality...
USP–NF PF 51(5) Draft RELEASED - Featured Image

USP–NF PF 51(5) Draft: Updates in Microbiology, Distribution, and Dosage Form Guidance

USP–NF PF 51(5) draft introduces updates in microbiology, transport, particulates, and dosage form guidance, emphasizing risk-based GMP compliance....
PDF revision on sub-visible particulate contamination in products

PDG Publishes Major Revision to General Chapter on Sub-Visible Particulate Contamination

PDG updates Q09 on sub-visible particulate contamination after 20 years, harmonising standards for safer parenteral medicines....
ICH Q3E Draft Guideline on extractablesICH Q3E Draft Guideline on extractables and leachables - Featured Image and leachables

ICH Q3E Draft Guideline on Extractables and Leachables

ICH Q3E draft outlines global guidance for Extractables & Leachables, covering scope, risk assessment, AET, and regulatory expectations....
Annex 22 Draft: Regulatory Guidance - Featured Image

Annex 22 Draft: Regulatory Guidance on AI Use in GMP

Annex 22 - EU's new draft regulatory framework for AI in GMP, focusing on model validation, performance, and risk management...
EU GMP Guidelines draft updates: Chapter 4, Annex 11, and new Annex 22 - What is about to change?

2025 EU GMP Draft Updates: Chapter 4, Annex 11, and Annex 22 – What’s Changing?

The 2025 EU GMP draft revisions to Chapter 4, Annex 11, and Annex 22 bring major changes to documentation, computerized...
USP Releases New Draft Proposals in Pharmacopeial Forum 51(4) - Featured Image

USP–NF PF 51(4) Draft Published

USP–NF PF 51(4) introduces draft chapters on data integrity, suspensions, disinfectants, chemometrics, and analytical lifecycle, impacting GMP pharma operations....
mdcg-2019-11-rev.1-mdr-news

MDCG 2019-11 Rev.1: Updated Guidance on Software Qualification and Classification under MDR and IVDR

MDCG 2019-11 Rev.1 updates software qualification and classification under MDR/IVDR with new rules, modular guidance, and conformity insights....

BECOME A GMP INSIDER

Stay in touch and be the first to get the latest GMP News!